Glomerular Stem Cell Isolation for Kidney Regeneration

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current stem cell technologies lack multipotent human mesenchymal stem cells capable of differentiating into various glomerular cell types and exhibiting self-renewal abilities, making them unsuitable for effective regenerative medicine applications, particularly for renal injuries and diseases.

Innovation Solution

Isolation and characterization of multipotent human mesenchymal stem cells from decapsulated adult human kidney glomeruli, specifically CD133 negative, CD146 positive, CD34 negative, and CD105 positive cells, which can differentiate into podocytes, mesangial, and endothelial cells, and possess remarkable self-renewal and clonogenic abilities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If stem cells are isolated from human adult kidney, then they can be used for regenerative medicine without ethical concerns, but they lack self-renewal abilities and multipotency

Engineering Contradiction:

Improvemultipotency and self-renewal abilityVSAvoidsuitability for regenerative medicine

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The invention extracts and isolates a specific stem cell population from human adult kidney tissue using flow cytometry-based cell sorting. The process identifies and separates CD133+CD24+ cells from the complex kidney tissue matrix, obtaining a purified stem cell population that exhibits both multipotency and self-renewal capabilities, thereby resolving the contradiction between ethical suitability and functional reliability

Inventive Principle:

Principle #2Taking out (Extraction)

Solution Approach 2:

The invention changes the characterization parameters of isolated kidney stem cells by identifying specific surface markers (CD133 and CD24) that define the multipotent population. By using these molecular parameters to guide isolation and validation, the method transforms ordinary kidney-resident cells into a reliably multipotent and self-renewing stem cell population suitable for regenerative medicine

Inventive Principle:

Principle #35Parameter changes

2Adaptability or versatility

If embryonic stem cells are used, then multipotency and self-renewal abilities are achieved, but ethical concerns arise

Engineering Contradiction:

ImprovemultipotencyVSAvoidethical concerns

Core Design Contradiction:

Adaptability or versatilityVSObject-affected harmful factors

Solution Approach 1:

The invention uses adult kidney tissue as an intermediary source that contains stem cells with properties similar to embryonic stem cells. The adult kidney serves as a morally acceptable alternative that mediates between the need for multipotent cells and ethical constraints, providing CD133+CD24+ cells that can differentiate into multiple lineages without involving embryo destruction

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention replaces the expensive and ethically problematic embryonic stem cell lines with adult-derived stem cells that can be obtained from surgical kidney samples. These adult-derived cells serve as a sustainable, ethically acceptable alternative that eliminates the need for ongoing embryonic tissue procurement while maintaining therapeutic potential

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

Data Source

PatentUS9499796B2Isolated multipotent mesenchymal stem cell from human adult glomeruli (HGL-MSC), a method of preparing thereof and uses thereof in the regenerative medicine of the kidney

Publication Date: 2016.11.22 FRESENIUS MEDICAL CARE DEUTSCHLAND GMBH

AI summary

The invention relates to an isolated multipotent glomerular mesenchymal stem cell derived from adult human kidney (hGL-MSC), which is characterized by the marker profile CD133−, CD146+, CD34− and CD105+. A method of preparing the hGL-MSC of the invention form decapsulated glomeruli is also disclosed, as well as the uses of the hGL-MSC of the invention in the regenerative treatment of the kidney, particularly for the treatment of injuries or diseases affecting renal glomeruli.